Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)

Molecular and Cellular Endocrinology

Volumn 386, Issue 1-2, 2014, Pages 2-15

  Thakker, Rajesh V ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Histone methylation; Neuroendocrine tumors; Pancreatic islet; Parathyroid; Pituitary; Tumors

Indexed keywords

PEPTIDES AND PROTEINS; PROTEIN MENIN; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CLINICAL FEATURE; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENDOCRINE TUMOR; EPIGENETICS; FAMILIAL CANCER; GENE MUTATION; GENETIC ASSOCIATION; GENETIC REGULATION; GENETIC SCREENING; HUMAN; MEN1 GENE; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 4; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPIC VARIATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION; TUMOR DIAGNOSIS;

HISTONE METHYLATION; NEUROENDOCRINE TUMORS; PANCREATIC ISLET; PARATHYROID; PITUITARY; TUMORS;

HUMANS; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PROTO-ONCOGENE PROTEINS;

EID: 84896703310     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.08.002     Document Type: Review

References (83)

1. Agarwal S.K., Jothi R. Genome-wide characterization of menin-dependent H3K4me3 reveals a specific role for menin in the regulation of genes implicated in MEN1-like tumors. PLoS One 2012, 7:e37952.
2. Agarwal S.K., Kester M.B., Debelenko L.V., Heppner C., Emmert-Buck M.R., Skarulis M.C., et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum. Mol. Genet. 1997, 6:1169-1175.
3. Agarwal S.K., Guru S.C., Heppner C., Erdos M.R., Collins R.M., Park S.Y., et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999, 96:143-152.
4. Akerstrom G., Hellman P. Surgery on neuroendocrine tumours. Best Pract. Res. Clin. Endocrinol. Metab. 2007, 21:87-109.
5. Bassett J.H., Forbes S.A., Pannett A.A., Lloyd S.E., Christie P.T., Wooding C., et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am. J. Hum. Genet. 1998, 62:232-244.
6. Belar O., De la Hoz C., Perez-Nanclares G., Castano L., Gaztambide S. Novel mutations in MEN1, CDKN1B and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain. Clin. Endocrinol. (Oxf.) 2012, 76:719-724.
7. Benson L., Ljunghall S., Akerstrom G., Oberg K. Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1. Am. J. Med. 1987, 82:731-737.
8. Brandi M.L., Gagel R.F., Angeli A., Bilezikian J.P., Beck-Peccoz P., Bordi C., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 2001, 86:5658-5671.
9. Burgess J.R., Greenaway T.M., Shepherd J.J. Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1. J. Int. Med. 1998, 243:465-470.
10. Burgess J.R., Nord B., David R., Greenaway T.M., Parameswaran V., Larsson C., et al. Phenotype and phenocopy: the relationship between genotype and clinical phenotype in a single large family with multiple endocrine neoplasia type 1 (MEN1). Clin. Endocrinol. (Oxf.) 2000, 53:205-211.
11. Calender A., Giraud S., Lenoir G.M., Cougard P., Chanson P., Proye C. [Hereditary multiple endocrine neoplasia. New genetic data and clinical applications in type 1 multiple endocrine neoplasia]. Presse Med. 1995, 24:542-546.
12. Cavaco B.M., Domingues R., Bacelar M.C., Cardoso H., Barros L., Gomes L., et al. Mutational analysis of Portuguese families with multiple endocrine neoplasia type 1 reveals large germline deletions. Clin. Endocrinol. (Oxf.) 2002, 56:465-473.
13. Chandrasekharappa S.C., Guru S.C., Manickam P., Olufemi S.E., Collins F.S., Emmert-Buck M.R., et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997, 276:404-407.
14. Dean P.G., van Heerden J.A., Farley D.R., Thompson G.B., Grant C.S., Harmsen W.S., et al. Are patients with multiple endocrine neoplasia type I prone to premature death?. World J. Surg. 2000, 24:1437-1441.
15. Dreijerink K.M., Mulder K.W., Winkler G.S., Hoppener J.W., Lips C.J., Timmers H.T. Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res. 2006, 66:4929-4935.
16. Fernandez A., Karavitaki N., Wass J.A. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf.) 2010, 72:377-382.
17. Flanagan D.E., Armitage M., Clein G.P., Thakker R.V. Prolactinoma presenting in identical twins with multiple endocrine neoplasia type 1. Clin. Endocrinol. (Oxf.) 1996, 45:117-120.
18. Friedman E., Sakaguchi K., Bale A.E., Falchetti A., Streeten E., Zimering M.B., et al. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. N. Engl. J. Med. 1989, 321:213-218.
19. Gao S.B., Feng Z.J., Xu B., Wu Y., Yin P., Yang Y., et al. Suppression of lung adenocarcinoma through menin and polycomb gene-mediated repression of growth factor pleiotrophin. Oncogene 2009, 28:4095-4104.
20. Goudet P., Murat A., Binquet C., Cardot-Bauters C., Costa A., Ruszniewski P., et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J. Surg. 2010, 34:249-255.
21. Grembecka J., He S., Shi A., Purohit T., Muntean A.G., Sorenson R.J., et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 2012, 8:277-284.
22. Guru S.C., Goldsmith P.K., Burns A.L., Marx S.J., Spiegel A.M., Collins F.S., et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc. Natl. Acad. Sci. USA 1998, 95:1630-1634.
23. Gurung B., Feng Z., Iwamoto D.V., Thiel A., Jin G., Fan C.M., et al. Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome. Cancer Res. 2013, 73:2650-2658.
24. Hannan F.M., Nesbit M.A., Christie P.T., Fratter C., Dudley N.E., Sadler G.P., et al. Familial isolated primary hyperparathyroidism caused by mutations of the MEN1 gene. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4:53-58.
25. Hao W., Skarulis M.C., Simonds W.F., Weinstein L.S., Agarwal S.K., Mateo C., et al. Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J. Clin. Endocrinol. Metab. 2004, 89:3776-3784.
26. Heppner C., Bilimoria K.Y., Agarwal S.K., Kester M., Whitty L.J., Guru S.C., et al. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 2001, 20:4917-4925.
27. Huang J., Gurung B., Wan B., Matkar S., Veniaminova N.A., Wan K., et al. The same pocket in menin binds both MLL and JunD but has opposite effects on transcription. Nature 2012, 482:542-546.
28. Hughes C.M., Rozenblatt-Rosen O., Milne T.A., Copeland T.D., Levine S.S., Lee J.C., et al. Menin associates with a trithorax family histone methyltransferase complex and with the Hoxc8 locus. Mol. Cell 2004, 13:587-597.
29. Hussein N., Casse H., Fontaniere S., Morera A.M., Asensio M.J., Bakeli S., et al. Reconstituted expression of menin in Men1-deficient mouse Leydig tumour cells induces cell cycle arrest and apoptosis. Eur. J. Cancer 2007, 43:402-414.
30. Imamura M., Komoto I., Ota S., Hiratsuka T., Kosugi S., Doi R., et al. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J. Gastroenterol. 2011, 17:1343-1353.
31. Karnik S.K., Hughes C.M., Gu X., Rozenblatt-Rosen O., McLean G.W., Xiong Y., et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc. Natl. Acad. Sci. USA 2005, 102:14659-14664.
32. Kim Y.S., Burns A.L., Goldsmith P.K., Heppner C., Park S.Y., Chandrasekharappa S.C., et al. Stable overexpression of MEN1 suppresses tumorigenicity of RAS. Oncogene 1999, 18:5936-5942.
33. Kim H., Lee J.E., Cho E.J., Liu J.O., Youn H.D. Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res. 2003, 63:6135-6139.
34. Kim H., Lee J.E., Kim B.Y., Cho E.J., Kim S.T., Youn H.D. Menin represses JunD transcriptional activity in protein kinase C theta-mediated Nur77 expression. Exp. Mol. Med. 2005, 37:466-475.
35. Knudson A.G., Strong L.C., Anderson D.E. Heredity and cancer in man. Prog. Med. Genet. 1973, 9:113-158.
36. La P., Desmond A., Hou Z., Silva A.C., Schnepp R.W., Hua X. Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression. Oncogene 2006, 25:3537-3546.
37. La P., Yang Y., Karnik S.K., Silva A.C., Schnepp R.W., Kim S.K., et al. Menin-mediated caspase 8 expression in suppressing multiple endocrine neoplasia type 1. J. Biol. Chem. 2007, 282:31332-31340.
38. Larsson C., Skogseid B., Oberg K., Nakamura Y., Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988, 332:85-87.
39. Lemos M.C., Thakker R.V. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat. 2008, 29:22-32.
40. Lin S.Y., Elledge S.J. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 2003, 113:881-889.
41. Lyons J., Landis C.A., Harsh G., Vallar L., Grunewald K., Feichtinger H., et al. Two G protein oncogenes in human endocrine tumors. Science 1990, 249:655-659.
42. Marx S., Spiegel A.M., Skarulis M.C., Doppman J.L., Collins F.S., Liotta L.A. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann. Int. Med. 1998, 129:484-494.
43. McCarthy N. Anticancer drugs: targeting menin. Nat. Rev. Drug Discov. 2012, 11:190.
44. Milne T.A., Hughes C.M., Lloyd R., Yang Z., Rozenblatt-Rosen O., Dou Y., et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl. Acad. Sci. USA 2005, 102:749-754.
45. Newey P.J., Thakker R.V. Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice. Endocr. Pract. 2011, 17(Suppl. 3):8-17.
46. Newey P.J., Jeyabalan J., Walls G.V., Christie P.T., Gleeson F.V., Gould S., et al. Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors. J. Clin. Endocrinol. Metab. 2009, 94:3640-3646.
47. Norton J.A., Jensen R.T. Role of surgery in Zollinger-Ellison syndrome. J. Am. Coll. Surg. 2007, 205:S34-S37.
48. Norton J.A., Fraker D.L., Alexander H.R., Venzon D.J., Doppman J.L., Serrano J., et al. Surgery to cure the Zollinger-Ellison syndrome. N. Eng. J. Med. 1999, 341:635-644.
49. Olufemi S.E., Green J.S., Manickam P., Guru S.C., Agarwal S.K., Kester M.B., et al. Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. Hum. Mutat. 1998, 11:264-269.
50. Pannett A.A., Thakker R.V. Somatic mutations in MEN type 1 tumors, consistent with the Knudson "two-hit" hypothesis. J. Clin. Endocrinol. Metab. 2001, 86:4371-4374.
51. Pellegata N.S., Quintanilla-Martinez L., Siggelkow H., Samson E., Bink K., Hofler H., et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. USA 2006, 103:15558-15563.
52. Prezant T.R., Levine J., Melmed S. Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors. J. Clin. Endocrinol. Metab. 1998, 83:1388-1391.
53. Roudaia L., Speck N.A. A MENage a Trois in leukemia. Cancer Cell 2008, 14:3-5.
54. Scacheri P.C., Davis S., Odom D.T., Crawford G.E., Perkins S., Halawi M.J., et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet. 2006, 2:e51.
55. Scarsbrook A.F., Thakker R.V., Wass J.A., Gleeson F.V., Phillips R.R. Multiple endocrine neoplasia: spectrum of radiologic appearances and discussion of a multitechnique imaging approach. Radiographics 2006, 26:433-451.
56. Schnepp R.W., Hou Z., Wang H., Petersen C., Silva A., Masai H., et al. Functional interaction between tumor suppressor menin and activator of S-phase kinase. Cancer Res. 2004, 64:6791-6796.
57. Schreinemakers J.M., Pieterman C.R., Scholten A., Vriens M.R., Valk G.D., Rinkes I.H. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. World J. Surg. 2011, 35:1993-2005.
58. Shen H.C., Rosen J.E., Yang L.M., Savage S.A., Burns A.L., Mateo C.M., et al. Parathyroid tumor development involves deregulation of homeobox genes. Endocr. Relat. Cancer 2008, 15:267-275.
59. Shi A., Murai M.J., He S., Lund G., Hartley T., Purohit T., et al. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 2012, 120:4461-4469.
60. Soares B.S., Eguchi K., Frohman L.A. Tumor deletion mapping on chromosome 11q13 in eight families with isolated familial somatotropinoma and in 15 sporadic somatotropinomas. J. Clin. Endocrinol. Metab. 2005, 90:6580-6587.
61. Sowa H., Kaji H., Hendy G.N., Canaff L., Komori T., Sugimoto T., et al. Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2. J. Biol. Chem. 2004, 279:40267-40275.
62. Stalberg P., Grimfjard P., Santesson M., Zhou Y., Lindberg D., Gobl A., et al. Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. J. Clin. Endocrinol. Metab. 2004, 89:2326-2337.
63. Stratakis C.A., Schussheim D.H., Freedman S.M., Keil M.F., Pack S.D., Agarwal S.K., et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 2000, 85:4776-4780.
64. Thakker R.V. Multiple endocrine neoplasia-syndromes of the twentieth century. J. Clin. Endocrinol. Metab. 1998, 83:2617-2620.
65. Thakker R.V. Multiple endocrine neoplasia type 1. Endocrinology 2010, 2719-2741. Elsevier, Philadelphia. sixth ed. L. De Groot, J.L. Jameson (Eds.).
66. Thakker R.V., Bouloux P., Wooding C., Chotai K., Broad P.M., Spurr N.K., et al. Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N. Engl. J. Med. 1989, 321:218-224.
67. Thakker R.V., Pook M.A., Wooding C., Boscaro M., Scanarini M., Clayton R.N. Association of somatotrophinomas with loss of alleles on chromosome 11 and with gsp mutations. J. Clin. Invest. 1993, 91:2815-2821.
68. Thakker R.V., Newey P.J., Walls G.V., Bilezikian J., Dralle H., Ebeling P.R., et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 2012, 97:2990-3011.
69. Tham E., Grandell U., Lindgren E., Toss G., Skogseid B., Nordenskjold M. Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. J. Clin. Endocrinol. Metab. 2007, 92:3389-3395.
70. The European Consortium on MEN1 Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. Hum. Mol. Genet. 1997, 6:1177-1183.
71. Tonelli F., Fratini G., Nesi G., Tommasi M.S., Batignani G., Falchetti A., et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann. Surg. 2006, 244:61-70.
72. Trouillas J., Labat-Moleur F., Sturm N., Kujas M., Heymann M.F., Figarella-Branger D., et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am. J. Surg. Pathol. 2008, 32:534-543.
73. Trump D., Farren B., Wooding C., Pang J.T., Besser G.M., Buchanan K.D., et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Qjm 1996, 89:653-669.
74. Turner J.J., Christie P.T., Pearce S.H., Turnpenny P.D., Thakker R.V. Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type1 (MEN1). Hum. Mutat. 2010, 31:E1089-E1101.
75. Verges B., Boureille F., Goudet P., Murat A., Beckers A., Sassolas G., et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J. Clin. Endocrinol. Metab. 2002, 87:457-465.
76. Vierimaa O., Georgitsi M., Lehtonen R., Vahteristo P., Kokko A., Raitila A., et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312:1228-1230.
77. Waldmann J., Lopez C.L., Langer P., Rothmund M., Bartsch D.K. Surgery for multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. Br. J. Surg. 2010, 97:1528-1534.
78. Wang E.H., Ebrahimi S.A., Wu A.Y., Kashefi C., Passaro E., Sawicki M.P. Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res. 1998, 58:4417-4420.
79. Yang Y.J., Song T.Y., Park J., Lee J., Lim J., Jang H., et al. Menin mediates epigenetic regulation via histone H3 lysine 9 methylation. Cell Death Dis. 2013, 4:e583.
80. Yokoyama A., Cleary M.L. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 2008, 14:36-46.
81. Yokoyama A., Wang Z., Wysocka J., Sanyal M., Aufiero D.J., Kitabayashi I., et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell. Biol. 2004, 24:5639-5649.
82. Yumita W., Ikeo Y., Yamauchi K., Sakurai A., Hashizume K. Suppression of insulin-induced AP-1 transactivation by menin accompanies inhibition of c-Fos induction. Int. J. Cancer 2003, 103:738-744.
83. Zablewska B., Bylund L., Mandic S.A., Fromaget M., Gaudray P., Weber G. Transcription regulation of the multiple endocrine neoplasia type 1 gene in human and mouse. J. Clin. Endocrinol. Metab. 2003, 88:3845-3851.